drugset / Trial / NCT00815607

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

NCT00815607

Phase 1 Completed 12 enrolled Alaunos Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.

Timeline

Start
2009-04
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INXN-3001 Cell therapy Other
Subject veledimex Small molecule Oral

Indications